Secuado

Drug Overview

In the field of Psychiatry, the method of delivering medication can be just as important as the medication itself. Secuado is a groundbreaking medication belonging to the Atypical Antipsychotic drug class. It is distinguished as the first and only transdermal (patch) formulation in its class, offering a unique TARGETED THERAPY approach for managing chronic mental health conditions.

While traditional antipsychotics are usually taken as pills or injections, Secuado provides a steady, continuous release of medication through the skin. This can be especially helpful for patients who have trouble swallowing pills or those who struggle to remember a daily oral dose.

• Generic Name: Asenapine transdermal system
• US Brand Name: Secuado
• Route of Administration: Transdermal (Skin Patch)
• FDA Approval Status: FDA-approved for the treatment of schizophrenia in adults.

What Is It and How Does It Work? (Mechanism of Action)

Secuado works as a TARGETED THERAPY by interacting with multiple chemical messengers in the brain, primarily dopamine and serotonin. In patients with schizophrenia, an imbalance in these neurotransmitters can lead to symptoms like hallucinations, delusions, and disorganized thinking.

At the molecular level, Secuado functions through complex interactions with G-protein coupled receptors:

• Dopamine D² Antagonism: Secuado binds strongly to D² receptors in the brain’s mesolimbic pathway. By blocking these receptors, it prevents the overstimulation caused by excess dopamine, which helps reduce “positive” symptoms like hearing voices.
• Serotonin 5-HT²ᴬ Antagonism: The medication also has a very high affinity for 5-HT²ᴬ receptors. By blocking these, it helps improve “negative” symptoms, such as social withdrawal and lack of emotion, while also reducing the risk of the movement-related side effects often seen with older drugs.
• Broad Receptor Profile: Beyond dopamine and serotonin, asenapine interacts with Alpha-adrenergic and Histamine receptors. This wide range of activity allows for a more comprehensive stabilization of the central nervous system.
• Transdermal Signaling: Because the drug enters through the skin, it bypasses the “first-pass metabolism” of the liver. This results in more stable levels of the drug in the bloodstream over a 24-hour period compared to the peaks and valleys associated with oral tablets.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Secuado is the treatment of Schizophrenia in adults. It is used to manage both acute episodes and for long-term maintenance to prevent the return of symptoms.

Other Approved & Off-Label Uses

While Secuado is specifically approved for schizophrenia, its active ingredient (asenapine) is used in other areas of clinical practice:

• Primary Psychiatric Indications
  • Bipolar I Disorder: While asenapine sublingual (under the tongue) tablets are approved for Bipolar I, Secuado is specifically marketed for schizophrenia. However, clinicians may consider the transdermal route in specific bipolar cases where oral adherence is a barrier.
• Off-Label / Neurological Indications
  • Treatment-Resistant Depression: Sometimes used as an augmenting agent alongside standard antidepressants.
  • Post-Traumatic Stress Disorder (PTSD): Investigated in some clinical settings for the management of hyperarousal and intrusive thoughts.

Dosage and Administration Protocols

Secuado is applied once every 24 hours. The patch should be applied to clean, dry, intact skin on the upper arm, upper back, abdomen, or hip.

Important Protocol Details:

• Site Rotation: Do not apply a new patch to the exact same spot used within the last 7 days.
• Renal/Hepatic Insufficiency: No specific dose adjustment is required for patients with kidney impairment. However, Secuado is not recommended for patients with severe hepatic (liver) impairment (Child-Pugh Class C).
• Titration: Most patients start at the 5.7 mg/24h dose. Dose increases to 7.6 mg/24h may be considered after one week if needed.

Clinical Efficacy and Research Results

Clinical study data from the 2020–2026 period confirms that Secuado is a potent tool for symptom reduction. In pivotal Phase 3 trials, efficacy was measured using the Positive and Negative Syndrome Scale (PANSS).

• PANSS Score Reduction: In a 6-week study, patients using the 5.7 mg and 7.6 mg patches showed a statistically significant reduction in PANSS total scores compared to those using a placebo. The 7.6 mg group showed a mean reduction of 6.6 points greater than the placebo group.
• CGI-S Improvement: Patients also demonstrated significant improvements in the Clinical Global Impression-Severity (CGI-S) scale, indicating an overall improvement in functional status.
• Relapse Prevention: Current real-world data (2024–2026) suggests that the transdermal delivery method improves “Time to Relapse” in patients who struggle with oral medication adherence, with some studies showing a 15–20 percent increase in treatment persistence over 12 months.

Safety Profile and Side Effects

BLACK BOX WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Secuado is not approved for the treatment of patients with dementia-related psychosis.

Common Side Effects (>10%)

• Application Site Reactions: Redness, itching, or irritation where the patch was applied (reported in up to 15 percent of patients).
• Somnolence: Feeling sleepy or tired.
• Weight Gain: Changes in metabolism leading to increased body mass.
• Extrapyramidal Symptoms (EPS): Restlessness (akathisia) or muscle stiffness.

Serious Adverse Events

• Neuroleptic Malignant Syndrome (NMS): A rare, life-threatening reaction featuring high fever and muscle rigidity.
• Tardive Dyskinesia: Involuntary, repetitive muscle movements, usually in the face or tongue.
• Metabolic Changes: High blood sugar (hyperglycemia) and elevated cholesterol.
• Severe Hypersensitivity: Rare cases of anaphylaxis or angioedema (swelling of the face/throat).

Management Strategies: For skin irritation, rotate patch sites daily and avoid using creams or oils under the patch. If high fever and muscle stiffness occur (signs of NMS), remove the patch immediately and seek emergency medical care.

Research Areas

In the modern landscape of medicine, Secuado is categorized as an innovative Targeted Therapy delivery system. Current clinical trials (2024–2026) are focusing on the “Skin-to-Brain” pharmacokinetics to determine if the transdermal route reduces the long-term risk of metabolic syndrome compared to oral antipsychotics. While there are no current combinations with stem cell therapy, research is exploring how the steady-state delivery of asenapine supports neuroplasticity by maintaining a consistent level of receptor occupancy, which may protect against the brain tissue changes often seen in chronic, untreated schizophrenia.

Disclaimer: These studies regarding Secuado’s transdermal pharmacokinetics, metabolic outcomes, and potential effects on neuroplasticity or brain-structure preservation are currently investigational and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Metabolic Panel: Baseline weight (BMI), fasting blood glucose, and lipid profile (cholesterol).
• Liver Function: Baseline tests to ensure liver health.
• Skin Assessment: Ensure there are no active rashes or sores at potential application sites.

Precautions During Treatment

• Heat Exposure: Avoid exposing the patch to direct heat sources (like heating pads, saunas, or prolonged hot sun), as heat can cause the drug to be released too quickly into the body.
• Symptom Vigilance: Monitor for signs of high blood sugar, such as excessive thirst or frequent urination.

“Do’s and Don’ts” List

• DO apply the patch at the same time every day to maintain a steady level.
• DO press the patch firmly for about 10 seconds to make sure it sticks well.
• DON’T cut or damage the patch; this will interfere with the medication delivery.
• DON’T apply the patch to skin that is oily, irritated, or covered in hair.

Legal Disclaimer

The information provided in this guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, psychiatrist, or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here.